[1]
Blanchet, B.; Billemont, B.; Barete, S.; Garrigue, H.; Cabanes, L.; Coriat, R.; Francès, C.; Knebelmann, B.; Goldwasser, F. Toxicity of sorafenib: Clinical and molecular aspects. Expert Opin. Drug Saf., 2010, 9(2), 275-287.
[http://dx.doi.org/10.1517/14740330903510608] [PMID: 20078249]
[http://dx.doi.org/10.1517/14740330903510608] [PMID: 20078249]
[2]
Sangro, B.; Chan, S.L.; Meyer, T.; Reig, M.; El-Khoueiry, A.; Galle, P.R. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J. Hepatol., 2020, 72(2), 320-341.
[http://dx.doi.org/10.1016/j.jhep.2019.10.021] [PMID: 31954495]
[http://dx.doi.org/10.1016/j.jhep.2019.10.021] [PMID: 31954495]
[3]
Haanen, J.B.A.G.; Carbonnel, F.; Robert, C.; Kerr, K.M.; Peters, S.; Larkin, J.; Jordan, K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2017, 28(Suppl. 4), 119-142.
[http://dx.doi.org/10.1093/annonc/mdx225] [PMID: 28881921]
[http://dx.doi.org/10.1093/annonc/mdx225] [PMID: 28881921]
[4]
Brahmer, J.R.; Lacchetti, C.; Schneider, B.J.; Atkins, M.B.; Brassil, K.J.; Caterino, J.M.; Chau, I.; Ernstoff, M.S.; Gardner, J.M.; Ginex, P.; Hallmeyer, S.; Holter Chakrabarty, J.; Leighl, N.B.; Mammen, J.S.; McDermott, D.F.; Naing, A.; Nastoupil, L.J.; Phillips, T.; Porter, L.D.; Puzanov, I.; Reichner, C.A.; Santomasso, B.D.; Seigel, C.; Spira, A.; Suarez-Almazor, M.E.; Wang, Y.; Weber, J.S.; Wolchok, J.D.; Thompson, J.A. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol., 2018, 36(17), 1714-1768.
[http://dx.doi.org/10.1200/JCO.2017.77.6385] [PMID: 29442540]
[http://dx.doi.org/10.1200/JCO.2017.77.6385] [PMID: 29442540]
Call for Papers in Thematic Issues
04 August, 2024
Gut microbiota in gastrointestinal and non-gastrointestinal diseases
The complex interplay between gut microbiota and human health has become a focal point in medical research. For this reason, the aim of this special issue is to explore the multifaceted role of gut microbiota in both gastrointestinal and non-gastrointestinal diseases. Regarding the dynamic symbiosis between the microbial communities residing ...read more
Article Metrics
16
3